Search

Your search keyword '"Christopher P. Regan"' showing total 72 results

Search Constraints

Start Over You searched for: Author "Christopher P. Regan" Remove constraint Author: "Christopher P. Regan"
72 results on '"Christopher P. Regan"'

Search Results

1. Association of respiratory failure with inhibition of NaV1.6 in the phrenic nerve

2. Development and characterization of canine‐specific computational models to predict pulsatile arterial hemodynamics and ventricular‐arterial coupling

3. Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of Pain

4. Combining an in silico proarrhythmic risk assay with a tPKPD model to predict QTc interval prolongation in the anesthetized guinea pig assay

5. Characterization of an investigative safety pharmacology model to assess comprehensive cardiac function and structure in chronically instrumented conscious beagle dogs

6. Shortening of the electromechanical window in the ketamine/xylazine-anesthetized guinea pig model to assess pro-arrhythmic risk in early drug development

8. Combining an in silico pro-arrhythmic risk assay with a tPKPD model to predict QTc interval prolongation in the anesthetized guinea pig

9. Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor*

10. QT interval correction assessment in the anesthetized guinea pig

11. Cardiac drug-drug interaction between HCV-NS5B pronucleotide inhibitors and amiodarone is determined by their specific diastereochemistry

12. Animal Models for Cardiovascular Research

13. List of Contributors

14. Successful integrative approach of the pro-arrhythmic risk assessment of the multichannel ion channel inhibitor vanoxerine, via combination of in silico human cardiomyocyte models and in vivo guinea-pig electromechanical window assay

16. Characterization of a conscious, restrained, rabbit CV telemetry model for assessing hemodynamic and ECG risk liabilities in early drug research and development

17. Evaluation of clinically-relevant proarrhythmic ECG biomarkers in conscious beagle dogs using a newly developed multiple lead ECG telemetry implant

19. Measurement of heart rate variability (HRV) and spontaneous baroreflex sensitivity (sBRS) provides valuable information on compound-dependent cardiovascular effects to enhance safety risk assessment

20. Impact of in vitro ion channel protocols when assessing cardiac pro-arrhythmic risk with in silico models

21. Comparison of the Intrinsic Vasorelaxant and Inotropic Effects of the Antiarrhythmic Agents Vernakalant and Flecainide in Human Isolated Vascular and Cardiac Tissues

22. Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics

23. Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys

24. Attenuation of scratch-induced reactive astrogliosis by novel EphA4 kinase inhibitors

25. Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel

26. Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist

27. Long term assessment of blood pressure transducer drift in rhesus monkeys chronically instrumented with telemetry implants

28. Calcitonin Gene-Related Peptide Receptor Antagonism Does Not Affect the Severity of Myocardial Ischemia during Atrial Pacing in Dogs with Coronary Artery Stenosis

29. An improved automated method to quantitate infarct volume in triphenyltetrazolium stained rat brain sections

30. Atrial Antifibrillatory Effects of Structurally Distinct IKur Blockers 3-[(Dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-Phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in Dogs with Underlying Heart Failure

31. Smooth Muscle–Targeted Knockout of Connexin43 Enhances Neointimal Formation in Response to Vascular Injury

32. In Vivo Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker, (2-Isopropyl-5-methylcyclohexyl) Diphenylphosphine Oxide, in Rat and Nonhuman Primate

33. In Vivo Antiarrhythmic and Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker (2-Isopropyl-5-methylcyclohexyl) Diphenylphosphine Oxide

34. Integrated In Vitro Cardiac Safety Assessment of Hepatitis-C Virus Nucleotide Inhibitor (HCV-NI) Drug Interaction with Amiodarone: Translatability to Clinic

38. A Preclinical Paradigm to Assess the Potential Risk and In Vivo Mechanism(s) Responsible for the Bradyarrhythmia Observed in Hepatitis-C Virus (HCV) Infected Patients Treated with Direct-Acting Antivirals (DAAs) and Amiodarone

39. Development of a Smooth Muscle–Targeted Cre Recombinase Mouse Reveals Novel Insights Regarding Smooth Muscle Myosin Heavy Chain Promoter Regulation

41. Smooth Muscle–Specific Expression of the Smooth Muscle Myosin Heavy Chain Gene in Transgenic Mice Requires 5′-Flanking and First Intronic DNA Sequence

42. Interaction of CArG Elements and a GC-rich Repressor Element in Transcriptional Regulation of the Smooth Muscle Myosin Heavy Chain Gene in Vascular Smooth Muscle Cells

43. Pressure-independent effects of AT1-receptor antagonism on cardiovascular remodeling in aortic-banded rats

44. Early, Short-Term Treatment with Captopril Permanently Attenuates Cardiovascular Changes in Spontaneously Hypertensive Rats

45. MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans

46. Attenuation of scratch-induced reactive astrogliosis by novel EphA4 kinase inhibitors

47. Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines

49. Effect of calcitonin gene-related peptide receptor antagonism on the systemic blood pressure responses to mechanistically diverse vasomodulators in conscious rats

50. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries

Catalog

Books, media, physical & digital resources